Statistics, ethics, and probiotica
Richard D. Gill

TL;DR
This paper discusses ethical and statistical considerations in clinical trial monitoring, highlighting a case where misinterpretation of data led to continued testing of a harmful treatment, risking patient lives.
Contribution
It analyzes the implications of data monitoring errors in clinical trials, emphasizing the importance of correct statistical interpretation and ethical decision-making.
Findings
Misinterpretation of p-values can lead to unethical trial continuation.
Approximately five lives were potentially lost due to trial mismanagement.
The importance of clear statistical communication in clinical decision-making.
Abstract
A randomized clinical trial comparing an experimental new treatment to a standard therapy for a life-threatening medical condition should be stopped early on ethical grounds, in either of the following scenarios: (1) it has become overwhelmingly clear that the new treatment is better than the standard; (2) it has become overwhelmingly clear that the trial is not going to show that the new treatment is any better than the standard. The trial is continued in the third scenario: (3) there is a reasonable chance that the new treatment will finally turn out to be better than the standard, but we aren't sure yet. However, the (blinded) data monitoring committee in the "PROPATRIA" trial of an experimental probiotica treatment for patients with acute pancreatitis allowed the trial to continue at the half way interim analysis, in effect because there was still a good chance of proving that the…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsStatistical Methods in Clinical Trials · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical studies and practices
